An update on long-acting agents in HIV therapy

References

• 1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338(13), 853–860 (1998).
  MedlineGoogle Scholar
• 2. Lundgren JD, Babiker AG, Gordin F et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373(9), 795–807 (2015).
  Medline CASGoogle Scholar
• 3. Rodger AJ, Cambiano V, Phillips AN et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 393(10189), 2428–2438 (2019).
  MedlineGoogle Scholar
• 4. Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N. Engl. J. Med. 337(21), 1485–1490 (1997).
  Medline CASGoogle Scholar
• 5. Irvine C, Egan KJ, Shubber Z, Van Rompay KKA, Beanland RL, Ford N. Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies. Clin. Infect. Dis. 60(Suppl. 3), S165–S169 (2015).
  MedlineGoogle Scholar
• 6. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587–2599 (2010).
  Medline CASGoogle Scholar
• 7. Molina J-M, Capitant C, Spire B et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373(23), 2237–2246 (2015).
  Medline CASGoogle Scholar
• 8. Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy. Adv. Drug Deliv. Rev. 103, 144–156 (2016).
  Medline CASGoogle Scholar
• 9. FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection. (2021). www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection
  Google Scholar
• 10. Vocabria | European Medicines Agency. www.ema.europa.eu/en/medicines/human/EPAR/vocabria#authorisation-details-section
  Google Scholar
• 11. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. (2021). https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection
  Google Scholar
• 12. WHO recommends long-acting cabotegravir for HIV prevention. (2022). www.who.int/news/item/28-07-2022-who-recommends-long-acting-cabotegravir-for-hiv-prevention
  Google Scholar
• 13. Johns BA, Kawasuji T, Weatherhead JG et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J. Med. Chem. 56(14), 5901–5916 (2013).
  Medline CASGoogle Scholar
• 14. Swindells S, Andrade-Villanueva JF, Richmond GJ et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med. 382(12), 1112–1123 (2020).
  Medline CASGoogle Scholar
• 15. Orkin C, Arasteh K, Górgolas Hernández-Mora M et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 382(12), 1124–1135 (2020).
  Medline CASGoogle Scholar
• 16. Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 396(10267), 1994–2005 (2020).
  Medline CASGoogle Scholar
• 17. Orkin C, Bernal Morell E, Tan DHS et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV 8(11), e668–e678 (2021).
  Medline CASGoogle Scholar
• 18. Ramgopal MN, Castagna A, Cazanave C et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random. Lancet HIV 10(9), e566–e577 (2023).
  Medline CASGoogle Scholar
• 19. Karver TS, Pascual-Bernaldez M, Berni A et al. Factors associated with health care providers' preference for forgoing an oral lead-in phase when initiating long-acting injectable cabotegravir and rilpivirine in the SOLAR Clinical Trial. AIDS Patient Care STDS 37(1), 53–59 (2023).
  MedlineGoogle Scholar
• 20. Orkin C, Schapiro JM, Perno CF et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin. Infect. Dis. doi: 10.1093/cid/ciad370 (2023) (Online ahead of print).
  MedlineGoogle Scholar
• 21. Cutrell AG, Schapiro JM, Perno CF et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS 35(9), 1333–1342 (2021).
  Medline CASGoogle Scholar
• 22. Rusconi S, Santoro MM, Capetti AF, Gianotti N, Zazzi M. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions. Int. J. Antimicrob. Agents 60(3), 106627 (2022).
  Medline CASGoogle Scholar
• 23. Rizzardini G, Overton ET, Orkin C et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR Trials. J. Acquir. Immune Defic. Syndr. 85(4), 498–506 (2020).
  MedlineGoogle Scholar
• 24. Jeffrey JL, Clair MS, Wang P et al. Impact of integrase sequences from HIV-1 Subtypes A6/A1 on the in vitro potency of cabotegravir or rilpivirine. Antimicrob. Agents Chemother. 66(3), (2022).
  Google Scholar
• 25. Llibre JM, Kuritzkes DAR. Long-acting cabotegravir and rilpivirine: innovation, new challenges, and opportunities. Clin. Infect. Dis. 76(9), 1655–1657 (2023).
  Medline CASGoogle Scholar
• 26. Thoueille P, Alves Saldanha S, Schaller F et al. Real-life therapeutic concentration monitoring of long-acting cabotegravir and rilpivirine: preliminary results of an ongoing prospective observational study in Switzerland. Pharmaceutics 14(8), 1588 (2022).
  Medline CASGoogle Scholar
• 27. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2023 interim update). www.bhiva.org/hiv-1-treatment-guidelines
  Google Scholar
• 28. Gupta RK, Gregson J, Parkin N et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. 18(3), 346–355 (2018).
  MedlineGoogle Scholar
• 29. Bertagnolio S, Hermans L, Jordan MR et al. Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor-containing antiretroviral therapy: a systematic review and meta-analysis. J. Infect. Dis. 224(3), 377 (2021).
  Medline CASGoogle Scholar
• 30. Link JO, Rhee MS, Tse WC et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584(7822), 614–618 (2020).
  Medline CASGoogle Scholar
• 31. Paik J. Lenacapavir: First Approval. Drugs 82(14), 1499–1504 (2022).
  Medline CASGoogle Scholar
• 32. Segal-Maurer S, De Jesus E, Stellbrink H-J et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N. Engl. J. Med. 386(19), 1793–1803 (2022).
  Medline CASGoogle Scholar
• 33. Gupta SK, Berhe M, Crofoot G et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, Phase II trial. Lancet HIV 10(1), e15–e23 (2023).
  Medline CASGoogle Scholar
• 34. Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N. Engl. J. Med. 385(7), 595–608 (2021).
  Medline CASGoogle Scholar
• 35. Marzinke MA, Fogel JM, Wang Z et al. Extended analysis of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. Antimicrob. Agents Chemother. 67(4), e0005323 (2023).
  MedlineGoogle Scholar
• 36. Delany-Moretlwe S, Hughes JP, Bock P et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399(10337), 1779–1789 (2022).
  Medline CASGoogle Scholar
• 37. Delany-Moretlwe S, Hughes JP, Bock P et al. Long acting cabotegravir: updated efficacy and safety results from HPTN 084 (Late-breaker Abstract OALBX0107). Presented at: 24th International AIDS Conference. (2022).
  Google Scholar
• 38. Anderson PL, Marzinke MA, Glidden DV. Updating the adherence-response for oral emtricitabine/tenofovir disoproxil fumarate for human immunodeficiency virus pre-exposure prophylaxis among cisgender women. Clin. Infect. Dis. 76(10), 1850–1853 (2023).
  Medline CASGoogle Scholar
• 39. Eshleman SH, Fogel JM, Halvas EK et al. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. J. Infect. Dis. 226(12), 2170–2180 (2022).
  Medline CASGoogle Scholar
• 40. Jamieson L, Johnson LF, Nichols BE et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV 9(12), e857–e867 (2022).
  Medline CASGoogle Scholar
• 41. Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection. https://clinicaltrials.gov/ct2/show/NCT04994509
  Google Scholar
• 42. Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection. https://clinicaltrials.gov/ct2/show/NCT04925752
  Google Scholar
• 43. Ludovici DW, De Corte BL, Kukla MJ et al. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorganic Med. Chem. Lett. 11(17), 2235–2239 (2001).
  Medline CASGoogle Scholar
• 44. Van Herrewege Y, Michiels J, Van Roey J et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48(1), 337–339 (2004).
  Medline CASGoogle Scholar
• 45. EMA. Dapivirine: summary of product characteristics. (2020).
  Google Scholar
• 46. Van Damme L, Corneli A, Ahmed K et al. Preexposure prophylaxis for HIV infection among african Women. N. Engl. J. Med. 367(5), 411–422 (2012).
  Medline CASGoogle Scholar
• 47. Marrazzo JM, Ramjee G, Richardson BA et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372(6), 509–518 (2015).
  MedlineGoogle Scholar
• 48. Baeten JM, Palanee-Phillips T, Brown ER et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med. 375(22), 2121–2132 (2016).
  Medline CASGoogle Scholar
• 49. Nel A, van Niekerk N, Kapiga S et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N. Engl. J. Med. 375(22), 2133–2143 (2016).
  Medline CASGoogle Scholar
• 50. The REACH Study (MTN-034) | Microbicide Trials Network. www.mtnstopshiv.org/news/reach-study-mtn-034
  Google Scholar
• 51. Baeten JM, Palanee-Phillips T, Mgodi NM et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV 8(2), e87–e95 (2021).
  Medline CASGoogle Scholar
• 52. Nel A, van Niekerk N, Van Baelen B et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV 8(2), e77–e86 (2021).
  Medline CASGoogle Scholar
• 53. Bunge K, Balkus J, Mhlanga F et al. DELIVER: a safety study of a dapivirine vaginal ring and oral PrEP during pregnancy (Abstract n. 127). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 54. Owor M, Noguchi L, Horne E et al. Dapivirine ring safety and drug detection in breastfeeding mother-infant pairs (Abstract n. 785). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 55. Baker Z, Javanbakht M, Moore J et al. A qualitative study on the acceptability of and adherence to a vaginal ring for HIV prophylaxis among adolescent girls. J. Acquir. Immune Defic. Syndr. 87(3), 944–950 (2021).
  MedlineGoogle Scholar
• 56. Michailidis E, Huber AD, Ryan EM et al. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J. Biol. Chem. 289(35), 24533–24548 (2014).
  Medline CASGoogle Scholar
• 57. Michailidis E, Marchand B, Kodama EN et al. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 284(51), 35681–35691 (2009).
  Medline CASGoogle Scholar
• 58. Schürmann D, Rudd DJ, Zhang S et al. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase. Lancet HIV 7(3), e164–e172 (2020).
  MedlineGoogle Scholar
• 59. Lai MT, Feng M, Xu M et al. Doravirine and islatravir have complementary resistance profiles and create a combination with a high barrier to resistance. Antimicrob. Agents Chemother. 66(5), e0222321 (2022).
  MedlineGoogle Scholar
• 60. Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV. https://clinicaltrials.gov/ct2/show/NCT05052996
  Google Scholar
• 61. Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]. https://clinicaltrials.gov/ct2/show/NCT04564547
  Google Scholar
• 62. Diamond TL, Ngo W, Xu M et al. Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile from approved nucleoside reverse transcriptase inhibitors (NRTIs). Antimicrob. Agents Chemother. 66(6), e0013322 (2022).
  MedlineGoogle Scholar
• 63. Molina JM, Yazdanpanah Y, Afani Saud A et al. Efficacy and safety of oral islatravir once daily in combination with doravirine through 96 weeks for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine. J. Acquir. Immune Defic. Syndr. 91(1), 68–72 (2022).
  Medline CASGoogle Scholar
• 64. Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection. www.merck.com/news/merck-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection/
  Google Scholar
• 65. Squires KE, Correll T, Robertson MN et al. Effect of Islatravir on total lymphocyte and lymphocyte subset counts (Abstract n. 192). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 66. Vargo R, Robey S, Zang X et al. Modeling and simulation to optimize islatravir once daily (QD) doses in HIV treatment naive and virologically suppressed populations. Presented at: HIV Glasgow. (2022).
  Google Scholar
• 67. Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection – Merck.com. https://www.merck.com/news/merck-to-initiate-new-phase-3-clinical-program-with-lower-dose-of-daily-oral-islatravir-in-combination-with-doravirine-for-treatment-of-people-with-hiv-1-infection/
  Google Scholar
• 68. Diamond TL, Lai MT, Feng M et al. Resistance profile of MK-8507, a novel NNRTI suitable for weekly oral HIV treatment (Abstract n. 129). Presented at: 28th Conference on Retroviruses and Opportunistic Infections (CROI). (2021).
  Google Scholar
• 69. Schürmann D, Rudd DJ, Schaeffer A et al. Single oral doses of MK-8507, a novel non-nucleoside reverse transcriptase inhibitor, suppress HIV-1 RNA for a week. J. Acquir. Immune Defic. Syndr. 89(2), 191–198 (2022).
  Medline CASGoogle Scholar
• 70. Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014). https://clinicaltrials.gov/ct2/show/NCT05093972
  Google Scholar
• 71. MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004). https://clinicaltrials.gov/ct2/show/NCT05494736
  Google Scholar
• 72. Shcherbakov DN, Bakulina AY, Karpenko LI, Ilyichev AA. Broadly neutralizing antibodies against HIV-1 as a novel aspect of the immune response. Acta. Naturae. 7(4), 11–21 (2015).
  Medline CASGoogle Scholar
• 73. Dufloo J, Planchais C, Frémont S et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nat. Commun. 13(1), 630 (2022).
  Medline CASGoogle Scholar
• 74. Hsu DC, Mellors JW, Vasan S. Can broadly neutralizing HIV-1 antibodies help achieve an ART-Free Remission? Front. Immunol. 12, 710044 (2021).
  Medline CASGoogle Scholar
• 75. Gruell H, Schommers P. Broadly neutralizing antibodies against HIV-1 and concepts for application. Curr. Opin. Virol. 54, 101211 (2022).
  Medline CASGoogle Scholar
• 76. Stephenson KE, Julg B, Tan CS et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase I clinical trial. Nat. Med. 27(10), 1718–1724 (2021).
  Medline CASGoogle Scholar
• 77. Cohen YZ, Butler AL, Millard K et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, Phase I study. PLOS ONE 14(8), e0219142 (2019).
  Medline CASGoogle Scholar
• 78. Mcfarland EJ, Cunningham CK, Muresan P et al. Safety, tolerability, and pharmacokinetics of a long-acting broadly neutralizing human immunodeficiency virus type 1 (HIV-1) monoclonal antibody VRC01LS in HIV-1-exposed newborn infants. J. Infect. Dis. 224(11), 1916–1924 (2021).
  Medline CASGoogle Scholar
• 79. Gaudinski MR, Houser KV, Doria-Rose NA et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a Phase I dose-escalation clinical trial. Lancet HIV 6(10), e667–e679 (2019).
  MedlineGoogle Scholar
• 80. Lynch RM, Boritz E, Coates EE et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7(319), 319ra206 (2015).
  MedlineGoogle Scholar
• 81. Scheid JF, Horwitz JA, Bar-On Y et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535(7613), 556–560 (2016).
  Medline CASGoogle Scholar
• 82. Crowell TA, Colby DJ, Pinyakorn S et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a Phase II, randomised, double-blind, placebo-controlled trial. Lancet HIV 6(5), e297–e306 (2019).
  MedlineGoogle Scholar
• 83. Bar KJ, Sneller MC, Harrison LJ et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375(21), 2037–2050 (2016).
  Medline CASGoogle Scholar
• 84. Gruell H, Gunst JD, Cohen YZ et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, Phase IIA trial. The Lancet Microbe 3(3), e203–e214 (2022).
  Medline CASGoogle Scholar
• 85. Corey L, Gilbert PB, Juraska M et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384(11), 1003–1014 (2021).
  Medline CASGoogle Scholar
• 86. Gunst JD, Pahus MH, Rosás-Umbert M et al. The impact of 3BNC117 and romidepsin treatment at ART initiation on HIV-1 persistence (Abstract n. 62). Presented at: 29th Conference on Retroviruses and Opportunistic Infections (CROI). (2022).
  Google Scholar
• 87. Gunst JD, Pahus MH, Rosás-Umbert M et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a Phase Ib/2a, randomized trial. Nat. Med. 28(11), 2424–2435 (2022).
  Medline CASGoogle Scholar
• 88. Gunst JD, Reikvam DH, McMahon J et al. The impact of 3BNC117, 10-1074, and lefitolimod on HIV-1 persistence: the TITAN trial (Abstract n. 136). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 89. Eron JJ, Little SR, Crofoot G et al. Lenacapavir with bNAbs GS-5423 and GS-2872 dosed every 6 months in People with HIV (Abstract n. 193). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 90. Mahomed S, Garrett N, Capparelli EV et al. Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for human immunodeficiency virus prevention. J. Infect. Dis. 226(3), 510–520 (2022).
  Medline CASGoogle Scholar
• 91. Mahomed S, Garrett N, Capparelli EV et al. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a Phase I, dose-escalation, randomised controlled trial. Lancet HIV 10(4), e230–e243 (2023).
  Medline CASGoogle Scholar
• 92. Volpe-Zanutto F, Vora LK, Tekko IA et al. Hydrogel-forming microarray patches with cyclodextrin drug reservoirs for long-acting delivery of poorly soluble cabotegravir sodium for HIV Pre-Exposure Prophylaxis. J. Control Release 348, 771–785 (2022).
  Medline CASGoogle Scholar
• 93. Pons-Faudoa FP, Sizovs A, Shelton KA et al. Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates. Adv. Ther. 4(3), 2000163 (2021).
  CASGoogle Scholar
• 94. Kovarova M, Benhabbour SR, Massud I et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun. 9(1), 4156 (2018).
  MedlineGoogle Scholar
• 95. Benhabbour SR, Kovarova M, Jones C et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat. Commun. 10(1), 4324 (2019).
  MedlineGoogle Scholar
• 96. Young IC, Massud I, Cottrell ML et al. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection. Nat. Commun. 14(1), 708 (2023).
  Medline CASGoogle Scholar
• 97. Pons-Faudoa FP, Di Trani N, Chua CYX et al. Ultra long-acting refillable islatravir implant fully protect NHP against SHIV (Abstract n. 165). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 98. Daly MB, Kim D, Li L et al. Vaginal PrEP efficacy of biodegradable implants in macaques (Abstract n. 989). Presented at: 30th Conference on Retroviruses and Opportunistic Infections (CROI). (2023).
  Google Scholar
• 99. Matthews RP, Zang X, Barrett SE et al. A randomized, double-blind, placebo-controlled, phase I trial of radiopaque islatravir-eluting subdermal implants for pre-exposure prophylaxis against HIV-1 infection. J. Acquir. Immune Defic. Syndr. 92(4), 310–316 (2023).
  Medline CASGoogle Scholar
• 100. Vora LK, Moffatt K, Tekko IA et al. Microneedle array systems for long-acting drug delivery. Eur. J. Pharm. Biopharm. 159, 44–76 (2021).
  Medline CASGoogle Scholar
• 101. Gachigua SG, Karuga R, Ngunjiri A et al. Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya. Front. Reprod. Heal. 5, 1125159 (2023).
  MedlineGoogle Scholar
• 102. UNAIDS. Full report – In Danger: UNAIDS Global AIDS Update 2022 | UNAIDS. (2022).
  Google Scholar
• 103. Ayuk BE, Yankam BM, Saah FI, Bain LE. Provision of injectable contraceptives by community health workers in sub-Saharan Africa: a systematic review of safety, acceptability and effectiveness. Hum. Resour. Health 20(1), (2022).
  MedlineGoogle Scholar